Ultragenyx Pharmaceutical (RARE) Operating Income (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Operating Income data on file, last reported at -$169.0 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$169.0 million, down 18.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$561.1 million (down 9.23% YoY), and the FY2025 annual result was -$535.0 million, changed 0.19% from the prior year.
• Operating Income declined to -$169.0 million in Q1 2026 per RARE's latest filing, from -$113.3 million in the prior quarter.
• Over five years, Operating Income peaked at -$107.9 million in Q2 2025 and troughed at -$225.1 million in Q3 2022.
• A 5-year average of -$144.6 million and a median of -$143.0 million in 2025 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2023: Operating Income sank 150.55% in 2022, then soared 35.53% in 2023.
• A 5-year view of Operating Income shows it stood at -$145.6 million in 2022, then advanced by 16.33% to -$121.8 million in 2023, then slipped by 0.38% to -$122.3 million in 2024, then advanced by 7.38% to -$113.3 million in 2025, then slumped by 49.18% to -$169.0 million in 2026.
• Business Quant data shows RARE's Operating Income at -$169.0 million in Q1 2026, -$113.3 million in Q4 2025, and -$170.9 million in Q3 2025.